Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis

This publication has 30 references indexed in Scilit:

• Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
  Journal of the American College of Cardiology, 2008
• Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
  The American Journal of Cardiology, 2008
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
  European Heart Journal, 2008
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
  Journal of Thrombosis and Haemostasis, 2007
• Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
  Pharmacogenetics and Genomics, 2007
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
  Blood, 2006
• Usefulness of Aspirin Resistance After Percutaneous Coronary Intervention for Acute Myocardial Infarction in Predicting One-Year Major Adverse Coronary Events
  The American Journal of Cardiology, 2006
• Relation of Aspirin Resistance to Coronary Flow Reserve in Patients Undergoing Elective Percutaneous Coronary Intervention
  The American Journal of Cardiology, 2005
• Variability in platelet responsiveness to clopidogrel among 544 individuals
  Journal of the American College of Cardiology, 2005
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance
  Circulation, 2004